Know All Your Treatment Options

May 17th, 2024

Scroll down for individual speaker videos

Full Event Video

"You can't know about things you have yet to discover."

Yogi Berra

MEET WITH OTHER PATIENTS, FAMILY MEMBERS, & CAREGIVERS

ASK QUESTIONS & FIND ANSWERS

2024 PRESENTING SPONSOR

GT Medical - GammaTile®

Surgically Targeted Radiation Therapy (STaRT) for Brain Tumors.
A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

2024 PRESENTING SPONSOR

Kiyatec

After receiving a cancer diagnosis, there are several tests that can help you learn more about your specific tumor. The 3D Predict™ test is one of them. It can show you which chemotherapy drugs will be most effective in your case—and just as importantly, which won’t.

2024 SPEAKER

Simon Hanft, MD

Neurosurgeon

Simon Hanft, MD is a board-certified neurosurgeon specializing in the care of brain tumors and tumors involving the spinal cord. He is the Section Chief of Neurosurgical Oncology for the Westchester Medical Center Health Network.

GammaTile: Improving the Lives of Patients with Brain Tumors

2024 SPEAKER

Eric Perreault

CEO, Kiyatec

Eric is a highly accomplished and passionate leader with 30 years of experience in medical sales and marketing with a particular focus on diagnostics. As Chief Executive Officer of Kiyatec Inc., he demonstrates exceptional leadership in the functional oncology space, overseeing sales, marketing, and operations. Eric has a proven track record of success, evident in his ability to secure fundraising for ongoing initiatives, rebrand products for patient-focused launches, and strategically restructure organizations for optimal performance.

Kiyatec Reimagined: Brain Cancer and Women's Cancer Product Focused Company

2024 SPEAKER

Dr. Jonathan Dewey

Servier Pharmaceuticals

Dr. Jonathan Dewey discusses the occurrence of genetic mutations in cancer cells. Identifying the presence of these mutations in the patient’s cancer cells is critical to understanding the prognosis and the best treatment options for that patient.

What IDH1/IDH2 Markers Are and Why They Are Relevant

2024 SPEAKER

Vyshak Venur, MD

Physician, Fred Hutch
Assistant Professor, Clinical Research Division, Fred Hutch
Assistant Professor, Division of Medical Oncology, University of Washington School of Medicine

“It’s not enough to give information — we must help people understand how a particular disease or treatment will affect them personally. That’s why I have a keen interest in learning about each patient. ”

— Dr. Venur

What the Potential Approval of Vorasidenib Means for Future Treatment of Low Grade Gliomas (LGGs)

2024 SPEAKER

Stephanie Key

Commercial Clinical Director

Developed exclusively for the streamlined treatment of brain tumors, lesions, and other conditions of the head and neck, ZAP-X® Gyroscopic Radiosurgery® platform redefines the future of radiosurgery and aspires to set new standards in SRS delivery.

ZAP-X® PATIENT BROCHURE

Introducing ZAP-X®: A New Type of Radiosurgery for the Brain Cancer Patient

2024 SPEAKER

Nicholas Avgeropoulos, M.D.

Global Therapeutic Area Lead - CNS Cancers

Nicholas G. Avgeropoulos, M.D. is a medical neuro-oncologist with over 25 years of experience focusing on clinical practice and translational research. His fellowships after neurology residency include the Medical University of South Carolina (neuroimmunology), Yale New Haven Hospital (neuropathology), and Massachusetts General Hospital (medical neuro-oncology), all focusing on different aspects of brain and spine tumor management. Dr. Avgeropoulos has most recently joined Novocure as the Global Therapeutic Area Lead for CNS Cancers.

Living with Glioblastoma (GBM) and Tumor Treating Fields (TTFields)

2024 SPEAKER

Shreya Prakash

End Brain Cancer Initiative

Ms. Shreya Prakash is the clinical research coordinator and patient navigator for the End Brain Cancer Initiative.

Using the xCures Platform to Increase a Personalized Approach to Treat Brain Cancer

During this event, our 2024 HOPE Award winner was announced!

2024 Event Agenda

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

EBCI In The News

Patient Stories

Patient Support Services

Patient Resource Center